<DOC>
	<DOCNO>NCT00506389</DOCNO>
	<brief_summary>The purpose trial investigate efficacy , safety tolerability esmirtazapine ( Org 50081 ) compare placebo patient chronic primary insomnia .</brief_summary>
	<brief_title>A Six Week , Double-Blind Randomized , Efficacy Safety , Sleep Lab Trial With Esmirtazapine ( Org 50081 ) ( P05707 )</brief_title>
	<detailed_description>Insomnia common complaint disorder throughout world . About one third population industrial country report difficulty initiate maintain sleep , result non-refreshing non-restorative sleep . The majority insomniac suffer chronically complaint . It report patient chronic insomnia lasting longer six month , 50 % past current mental disorder . This raise possibility treatment insomnia may reduce risk psychological condition . This double-blind , placebo-controlled , parallel , randomized clinical trial design assess efficacy safety esmirtazapine patient suffer chronic primary insomnia .</detailed_description>
	<mesh_term>Sleep Initiation Maintenance Disorders</mesh_term>
	<mesh_term>Mirtazapine</mesh_term>
	<criteria>Documented diagnosis chronic primary insomnia Other sleep disorder sleep apnea , restless leg syndrome , narcolepsy , sleep/wake rhythm disorder Has significant medical psychiatric illness cause sleep disorder Diagnosed major depressive disorder Substance abuse within past year Night worker work rotate shift Has serious head injury , stroke , epilepsy Has history bipolar disorder family ( immediate family ) history suicide Smokes 15 cigarette per day abstain smoke night sleep laboratory Drinks beverages contain 500 mg caffeine per day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Sleep Initiation Maintenance Disorders , Sleep Disorders , Intrinsic Dyssomnias , Sleep Disorders , Nervous System Diseases , Mental Disorders</keyword>
</DOC>